Nuvation Bio Inc.: Business Overview, Financials & Competitive Analysis
Nuvation Bio Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Nuvation Bio is a compelling long-term biotech investment following FDA approval and the strong early launch of IBTROZI (taletrectinib) for ROS1+ NSCLC with superior efficacy and rapid uptake. Ibtrozi's commercial launch is robust, with early patient uptake showing strong momentum. The company achieved an impressive revenue growth rate of.
What is Nuvation Bio Inc.'s industry? Nuvation Bio Inc. (nuvationbio.com) operates in Biopharmaceutical/Oncology. AskCyborg classifies Nuvation Bio Inc. under Biopharmaceutical/Oncology in its company registry.
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1...
Cyborg Score thesis
Nuvation Bio is a compelling long-term biotech investment following FDA approval and the strong early launch of IBTROZI...
Read the full analyst-debate transcript →Get the Latest Nuvation Bio Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeNuvation Bio Inc. Overview
Pro stress-test →Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company recently achieved FDA approval for its flagship therapy, Ibtrozi (taletrectinib), and is demonstrating strong early commercial traction.
Strategic Profile
Pro stress-test →The company is focused on developing and commercializing novel therapies for the most difficult-to-treat cancers, specifically targeting indications for which conventional therapies have failed, with a deep pipeline of differentiated and novel therapeutic candidates targeting critical pathways that cancer cells use to grow. Founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines.
Competitive Landscape
Pro stress-test →Nuvalent, Blueprint Medicines, Aura Biosciences, Arcus Biosciences, and Cullinan Therapeutics are some of the 60 competitors of Nuvation Bio. The company differentiates through its selective ROS1 inhibitor with superior brain penetration and central nervous system activity, enabling treatment of brain metastases - a significant unmet need in ROS1+ NSCLC.
Industry Context
Nuvation Bio Inc. operates in Biopharmaceutical/Oncology.
Key facts
Founded: 2018 · Headquarters: New York, United States · Employees: 218 · Revenue: $26.7M · Market cap: $1.95B